Data Presented at AACR Meeting Shows Bavituximab Equivalent Plus,Docetaxel Reduces Growth of Both Hormone-Dependent and,Hormone-Independent Prostate Cancer by Up to 94 Percent in,Preclinical Studies ( - Combination Therapy Significantly Dec...)

Navigation Links

Biology News Medicine News Biology Products Medicine Products Biology Definition Medicine Definition Biology Technology Medicine Technology Biology Dictionary Medicine Dictionary

HOME >> MEDICINE >> TECHNOLOGY

Data Presented at AACR Meeting Shows Bavituximab Equivalent Plus,Docetaxel Reduces Growth of Both Hormone-Dependent and,Hormone-Independent Prostate Cancer by Up to 94 Percent in,Preclinical Studies

- Combination Therapy Significantly Decreased Tumor Blood Vessel Density and Serum PSA Levels in Prostate Tumors -

LOS ANGELES and TUSTIN, Calif., April 17, 2007 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. , a clinical stage biopharmaceutical company developing targeted monoclonal antibodies for the treatment of cancer and hepatitis C virus (HCV) infection, today announced that preclinical data presented at the Centennial Annual Meeting of the American Association for Cancer Research (AACR) confirms that a mouse equivalent to Peregrine's novel monoclonal antibody bavituximab given in combination with docetaxel decreased the growth of common forms of prostate cancer significantly more than either agent alone. This increase in anti-tumor efficacy was achieved with no apparent increase in toxicity. Researchers also observed that in one tumor model, the combination significantly decreased the level of serum PSA, a biomarker for prostate cancer, and in both tumor types tested it was more effective in decreasing the density of the microvessels needed to support tumor growth and development.

"This data reaffirms the potential of bavituximab for the treatment of prostate cancer in combination with docetaxel and is particularly timely since we recently completed enrollment in our first human trial of bavituximab in combination with anti-cancer agents including docetaxel," said Steven W. King, president and CEO of Peregrine. "We look forward to assessing further bavituximab's anti-cancer potential in our ongoing clinical trials, as well as in new combination therapy clinical studies we will be initiating later this year."

In this study, the anti-phosphatidylserine (anti-PS) monoclonal antibody 2aG4 (a mouse equivalent antibody to bavituximab) was administered to male mice that had been injected with common forms of hormone dependent and hormone independent tumor cells. Docetaxel and 2aG4 alone
'"/>

Page: 1 2 3 4 5
Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
4. Clinical Data From Nymox BPH Drug To Be Presented at American Urological Association Meeting
5. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
6. ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data Presented at International Myeloma Workshop
7. Nymox Announces NX-1207 Data to Be Presented at Upcoming U.S. Urology Meetings
8. MEDIA ADVISORY: Subsets of Landmark Diabetes Trials Investigating MacroVascular Outcomes Presented at the American Diabetes Association 67th Scientific Sessions
9. Nymox Announces NX-1207 Data to Be Presented at Upcoming U.S. Urology Meetings
10. ConjuChem Biotechnologies Reports PC-DAC:Exendin-4 Albumin Conjugate Data Presented at American Diabetes Association Annual Meeting
11. New Data Presented on Micardis (Telmisartan) Tablets in Hypertensive Patients With Type 2 Diabetes

Post Your Comments:

(Date:5/22/2013)... May 22, 2013 Modern Medical announced today ... Launched in November 2012 in a test phase, ... to stop the rising opioid abuse in the ... program designed to protect employees, physicians and employers ... necessary balance to provide pain relief for the ...

(Date:5/22/2013)... 2013 STEPh, Inc., a full service medical ... their web site ( http://www.stephreports.com ) dedicated ... About STEPh Reports STEPh Reports are comprehensive ... Each STEPh Report assesses the competitive landscape by individual ... company, and specific key issues. STEPh Reports are written ...

(Date:5/22/2013)... 2013 MEDIFIRST SOLUTIONS, INC. (OTCQB: MFST) would ... some recent company developments. As Medifirst continues to expand ... with shareholders. Integrating social media into its investor relations ... will post updates on Twitter. The Facebook homepage is ... Says CEO Bruce J. Schoengood ...

Breaking Medicine Technology:Modern Medical Introduces Opioid Abuse Solution to the Workers' Compensation Industry 2 Scientific and Technical Evaluation of Pharmaceuticals, Inc. [STEPh, Inc.], Launches New Competitive Intelligence Web Site 2 Medifirst Solutions, Inc. Announces Update To Shareholders 2

[0] Modern Medical Introduces Opioid Abuse Solution to the Workers' Compensation Industry [0] Scientific and Technical Evaluation of Pharmaceuticals, Inc. [STEPh, Inc.], Launches New Competitive Intelligence Web Site [0] Medifirst Solutions, Inc. Announces Update To Shareholders

... Mass., May 19, 2011 Alere Inc. (NYSE: ALR ... their health at home through the merger of rapid diagnostics and ... its Series B Convertible Perpetual Preferred Stock (NYSE: ALR ... Series B stock in an amount per share equal to the ...

... a segment of BD (Becton, Dickinson and Company) (NYSE: ... BD MAX™ for use as an open system. ... molecular system designed to perform a broad range of molecular ... but also user-defined protocols and life science research applications. The ...

Cached Medicine Technology:BD Launches BD MAX™ System in U.S. to Empower Laboratories and Clinicians to Respond to Emerging Diseases 2 BD Launches BD MAX™ System in U.S. to Empower Laboratories and Clinicians to Respond to Emerging Diseases 3

Alere Inc. Declares Dividend on its Series B Convertible Perpetual Preferred Stock BD Launches BD MAX™ System in U.S. to Empower Laboratories and Clinicians to Respond to Emerging Diseases

(Date:5/22/2013)... New York, New York (PRWEB) May 22, 2013 ... a metal-on-metal version of the DePuy Pinnacle Hip Replacement ... underway in Texas Federal Court, Bernstein Liebhard LLP reports. ... Court has directed DePuy Orthopaedics to produce monitoring reports ... government into the company’s medical device marketing practices. ...

(Date:5/22/2013)... Diversity Focus and Handicap This Productions announce ... promotes awareness that physical disabilities do not stop people ... be held Friday, June 14th at 7:30 p.m. at ... Handicap This! can be purchased at http://www.diversityfocus.org . ... to which their mind is handicap accessible. Mike ...

(Date:5/22/2013)... May 22, 2013 Twenty student-led startup ... year participating in an intensive startup accelerator designed to ... or services and create local jobs as part of ... year the Edson initiative offers approximately 20 student teams ... mentorship and training to launch their for-profit, more-than-profit or ...

(Date:5/22/2013)... University of Michigan study challenges previous research that ... , The study, a collaboration between researchers at ... looks deeper into the controversial argument over whether ... for pitchers of the same race. It found ... Jason Winfree, associate professor of sport management at ...

(Date:5/22/2013)... (HealthDay News) -- Over the next two decades, the ... expected to more than double, topping more than $180 ... main factor driving the increase: an aging population. The ... American Stroke Association, was published May 22 in the ... the health care system," Dr. Bruce Ovbiagele, chairman of ...

[0] DePuy Pinnacle Lawsuit News: Bernstein Liebhard LLP Notes New Order in Federal Pinnacle Litigation Requiring Production of Monitoring Reports from Federal Investigation [0] Handicap This! Comes to Marion, Iowa [0] ASU Announces Edson Student Entrepreneur Initiative’s 2013-2014 Cohort [0] U-M study challenges notion that umpires call more strikes for pitchers of same race [0] Cost of Treating Strokes in U.S. Could Soar to $180B Annually by 2030: Report

... will play host to 800 women from 55 countries ... from November 27. // ,The four-day international congress ... for the first time in South Asia. The earlier ... (1999) and Stockholm (2002)., ,Among its main objectives, ...

... flu, even as the government has given approval to clinical ... latest outbreaks of the deadly H5N1 strain of the flu ... of Yunnan and the northwestern region of Ningxia, the agriculture ... in Yunnan's Chuxiong district Thursday, and 230 died in Yinchuan, ...

... project, launched with the aim to combat AIDS will exploit ... around the world to aid research and identify drugs used ... ,The Internet-based initiative, called FightAIDS@Home, aims to enlist about 100,000 ... a secure website when they would otherwise be idle., ...

... from bird flu and other diseases, the US health ... to hand over// passenger and crew lists on demand ... Atlanta-based Centers for Disease Control and Prevention (CDC), the ... threats, has proposed the regulatory overhaul. The CDC said ...

... of breast-feeding is associated with reduction in risk of ... studies have already provided evidence for improved insulin sensitivity ... their counterparts. ,The study is the first of ... lactation and Type 2 diabetes. More than 1,57,003 parous ...

... - Conservative groups in the United States, who had ... the "morning-after" pill, are now having no such qualms ... vaccines manufactured by Merck & Co. and GlaxoSmithKline are ... from the market, but concerns had been voiced about ...

Cached Medicine News:Health News:Delhi To Host International Women’s Congress From Nov 2 2 Health News:U.S. To Tighten Sick Passenger, Quarantine Rules 2 Health News:Breastfeeding To Reduce Risk Of Type 2 Diabetes 2 Health News:Religious groups overcome objections to cervical cancer vaccines 2

Delhi To Host International Women’s Congress From Nov 2 Three More Bird Flu Cases Reported By China Supercomputer Grid Enlists PCs To Combat AIDS U.S. To Tighten Sick Passenger, Quarantine Rules Breastfeeding To Reduce Risk Of Type 2 Diabetes Religious groups overcome objections to cervical cancer vaccines

... the ureter to be dilated immediately below ... base of the balloon allows fluoroscopic confirmation ... sterile in peel-open packages. Intended for one-time ... Straight Safety Wire Guide [.038 inch (0.97 ...

Used during the performance of balloon dilation procedures to inflate and deflate the balloon and measure the pressure within the balloon during the procedure. Supplied sterile in peel-open packages....

... Small 6.9 Fr Diameter with Two Large ... USA Series MICRO-6 Semi-Rigid Ureteroscope is the ... for diagnostic and therapeutic procedures. The ACMI ... time for procedures with minimal or no ...

Smooth, contoured visual obturator provides less traumatic insertion through the urethra and into the bladder....

Medicine Products:

Tipless Balloon Catheter Set Inflation Device Set USA Series MICRO-6 Semi-Rigid Ureteroscope S-Series Cystourethroscope Visual Obturator